Clinical Response for 12 Months or More to the First Advanced Therapy is Associated with a Significant Decrease in the Long-Term Risk of Hospitalization: A Nation-Wide Analysis of Patients From the UK Inflammatory Bowel Disease (IBD) BioResource
Inflammatory Bowel Diseases · 2026
DOI: 10.1093/ibd/izaf276 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2026. Verfasst von Kaung Yan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Digital Research Service, University of Nottingham, Nottingham, United Kingdom. Hauptthemen laut MEDLINE: Hospitalization, Crohn Disease, Colitis, Ulcerative, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Janssen Global Services, Horsham, PA, United States.
Abstract (Originalsprache)
Background and Aims It is unclear if a sustained response to the first advanced therapy affects the long-term risk of hospitalization in patients with inflammatory bowel disease (IBD). We have undertaken a retrospective analysis of clinical outcomes using the National Institute for Health and Care Research (NIHR) IBD BioResource database.
Methods
We included adult patients (≥18 years old) with Crohn disease (CD) or ulcerative colitis (UC) who received treatment with at least 1 advanced therapy. Treatment response was defined as clinical response or remission for 12 months or longer. The outcome was the incidence of IBD-related long-term risk of hospitalization, defined as admission for IBD-related surgery or disease exacerbation requiring intravenous corticosteroids over the duration of follow-up.
Results
A total of 15 531 patients (CD, 10 024; and UC, 5507) were included in the analysis. Overall, 82% of CD patients and 75.2% of UC patients experienced treatment response to their first advanced treatment. Treatment response to the first advanced therapy initiated was significantly associated with a lower long-term risk of hospitalization in both CD (odds ratio [OR], 0.826; 95% CI, 0.797-0.857) and UC (OR, 0.975; 95% CI, 0.954-0.997). The median (IQR) time (years) for hospitalization In CD responders was 2 (1-4) years and in CD nonresponders was 1.17 (1-3) years, P < .0001 and in UC responders was 1.38 (0.85-3) years and in UC nonresponders was 1 (0.65-2) years, P < .0019.
Conclusions
Treatment response to the first advanced treatment initiated is significantly associated with a lower long-term risk of hospitalization for IBD. Choosing the best therapy the first time may improve long-term outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Digital Research Service, University of Nottingham, Nottingham, United Kingdom.
- Department of GastroenterologyNottingham University Hospitals NHS trust, Nottingham, United Kingdom.
- Centre for Health Informatics, School of Medicine, University of Nottingham, Nottingham, United Kingdom.
- Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
- Janssen Global Services, Horsham, PA, United States.
- Janssen Pharmaceutica NV, Beerse, Belgium.
ORCID-Profile: Sudheer Kumar Vuyyuru, Myrlene Sanon, Gordon W Moran
Förderung
- Janssen Global Services, Horsham, PA, United States
Zitieren
APA
Yan, K., Vuyyuru, S. K., Taylor, A., Figueredo, G., Raine, T., Sanon, M., Naessens, D., Munje, C., & Moran, G. W. (2026). Clinical Response for 12 Months or More to the First Advanced Therapy is Associated with a Significant Decrease in the Long-Term Risk of Hospitalization: A Nation-Wide Analysis of Patients From the UK Inflammatory Bowel Disease (IBD) BioResource. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf276
Vancouver
Yan K, Vuyyuru SK, Taylor A, Figueredo G, Raine T, Sanon M, et al. Clinical Response for 12 Months or More to the First Advanced Therapy is Associated with a Significant Decrease in the Long-Term Risk of Hospitalization: A Nation-Wide Analysis of Patients From the UK Inflammatory Bowel Disease (IBD) BioResource. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izaf276
BibTeX
@article{Yan2026,
author = {Yan, Kaung and Vuyyuru, Sudheer Kumar and Taylor, Adam and Figueredo, Grazziela and Raine, Tim and Sanon, Myrlene and Naessens, Dominik and Munje, Chinmay and Moran, Gordon W},
title = {Clinical Response for 12 Months or More to the First Advanced Therapy is Associated with a Significant Decrease in the Long-Term Risk of Hospitalization: A Nation-Wide Analysis of Patients From the UK Inflammatory Bowel Disease (IBD) BioResource},
journal = {Inflammatory Bowel Diseases},
year = {2026},
doi = {10.1093/ibd/izaf276}
}
EUVIMED